92 related articles for article (PubMed ID: 3243325)
1. Pharmacokinetics of cadralazine in hypertensive patients.
Leonetti G; Parini J; Visconti M; Gradnik R
Eur J Drug Metab Pharmacokinet; 1988; 13(4):295-300. PubMed ID: 3243325
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats.
Terauchi Y; Watari S; Ishikawa S; Takeyama K; Sekine Y; Hashimoto M; Hayashi T
Arzneimittelforschung; 1988 Feb; 38(2):237-9. PubMed ID: 3370071
[TBL] [Abstract][Full Text] [Related]
4. Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients.
Catalano M; Parini J; Libretti A
Eur J Clin Pharmacol; 1983; 24(2):157-61. PubMed ID: 6840161
[TBL] [Abstract][Full Text] [Related]
5. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
Persson B; Granerus G; Wysocki M; Hedner T; Andersson OK
Eur J Clin Pharmacol; 1987; 31(5):513-8. PubMed ID: 2881788
[TBL] [Abstract][Full Text] [Related]
6. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.
Brunel P; Lecaillon JB; Guyene TT; Imhof P; Ménard J
Br J Clin Pharmacol; 1990 May; 29(5):503-9. PubMed ID: 2190629
[TBL] [Abstract][Full Text] [Related]
7. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
McTavish D; Young RA; Clissold SP
Drugs; 1990 Oct; 40(4):543-60. PubMed ID: 2083513
[TBL] [Abstract][Full Text] [Related]
8. Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
Catalano M; Parini J; Romano M; Libretti A
Eur J Clin Pharmacol; 1985; 28(2):135-8. PubMed ID: 3886402
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive activity of cadralazine in experimental hypertensive rats.
Takeyama K; Ikeno A; Minato H; Fukuya F; Nishimura S; Hosoki K; Kadokawa T
Arch Int Pharmacodyn Ther; 1988; 291():163-74. PubMed ID: 3365060
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients.
Lecaillon JB; Dubois JP; Darragon T; Motolese M; Racine A; Ducret F; Grouberman D; Cordonnier D; Chanard J; Glorioso M
Ther Drug Monit; 1991 Mar; 13(2):103-8. PubMed ID: 2053115
[TBL] [Abstract][Full Text] [Related]
11. Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.
Costa FV; Borghi C; Mussi A; Ambrosioni E
Eur J Clin Pharmacol; 1986; 30(2):145-50. PubMed ID: 3709638
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
Buoninconti R; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
[TBL] [Abstract][Full Text] [Related]
13. Hemorheologic effects of vasodilation in essential hypertension.
Wysocki M; Andersson OK; Persson B; Bagge U; Braide M
Angiology; 1996 Sep; 47(9):869-78. PubMed ID: 8810653
[TBL] [Abstract][Full Text] [Related]
14. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
[TBL] [Abstract][Full Text] [Related]
15. Effects of cadralazine on systemic blood pressure, renal function and plasma renin activity in anesthetized dogs.
Yukimura T; Miura K; Tanaka M; Higashio T; Sakaguchi S; Kuroda K; Yamamoto K
Arzneimittelforschung; 1988 Jan; 38(1):25-8. PubMed ID: 3284531
[TBL] [Abstract][Full Text] [Related]
16. [Influence of acetylation phenotype on the pharmacokinetics and pharmacodynamics data of cadralazine in normotensive subjects].
Brunel P; Lecaillon JB; Imhof P; Menard J
Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1257-60. PubMed ID: 2510657
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug.
Semeraro C; Dorigotti L; Banfi S; Carpi C
J Cardiovasc Pharmacol; 1981; 3(3):455-67. PubMed ID: 6168827
[TBL] [Abstract][Full Text] [Related]
18. Cadralazine pharmacokinetics--a pilot study.
Haglund K; Dahlqvist R; Emilsson H; Englund G
Eur J Clin Pharmacol; 1988; 35(5):571-2. PubMed ID: 3234466
[No Abstract] [Full Text] [Related]
19. Brachial artery cross-sectional area and distensibility before and after arteriolar vasodilatation in men with sustained essential hypertension.
Safar ME; London GM; Bouthier JA; Levenson JA; Laurent S
J Cardiovasc Pharmacol; 1987 Jun; 9(6):734-42. PubMed ID: 2442542
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
Strocchi E; Costa FV; Caldari R; Malini PL; Marata AM; Parini J; Ambrosioni E
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):519-23. PubMed ID: 6642790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
